Micro RNA Expression Analysis in B-Lineage Adult Acute Lymphoblastic Leukemia From ALL Trial, E2993, Including Patients With Various Cytogenetic and Molecular Abnormalities
| Registry | NCT01505699 |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 186 (Actual) |
| Sponsor | Eastern Cooperative Oncology Group (Network); collaborators: National Cancer Institute (NCI) |
| Conditions | Leukemia |
| Interventions | RNA analysis, cytogenetic analysis, microarray analysis, laboratory biomarker analysis (Genetic, other) |
| Dates | start 2012-01-06, primary completion 2012-02-06, completion 2012-02-06, first posted 2012-01-06, last updated 2017-05-17 |
Related Papers Related Patents Related Grants Related Experts
All trials for Leukemia All trials of RNA analysis All trials of cytogenetic analysis
RATIONALE: Studying samples of tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in samples from patients with acute lymphoblastic leukemia enrolled on ECOG-2993 clinical trial.
OBJECTIVES:
* To identify microRNAs that behave as oncogenes or as tumor suppressor genes in B-lineage acute lymphoblastic leukemia (ALL) in vitro and in vivo.
* To examine if single microRNA or signatures of microRNA correspond to different clinical outcomes in cytogenetically distinct B-ALL groups.
OUTLINE: RNA from archived samples are analyzed for microRNA expression profile in vitro and in vivo.
Sex: All, ages: 15 Years to 65 Years
DISEASE CHARACTERISTICS: * Samples from patients enrolled on ECOG-2993 * Samples from patients with recurrent cytogenetic abnormalities other than BCR-ABL, including MLL/AF4, E2A/PBX1, and TEL/AML1 PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified